The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors
ACS Pharmacology & Translational Science · 12.09.2025 · 8 (9) · 3090-3100
DOI: 10.1021/acsptsci.5c00265 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 14.08.2025. Verfasst von Ken Ellsworth und 19 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Biosciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Despite advances in anticoagulant drug discovery to establish a new standard of care, represented by Factor Xa (FXa) inhibitors, additional therapies are needed to address the concomitant bleeding risk posed by these agents. Factor XI (FXI) plays a key role in the intrinsic coagulation cascade contributing to thrombin generation and fibril formation, and there is an increasing weight of evidence supporting a comparable efficacy and superior safety profile of FXI-based oral anticoagulants. A novel allosteric mechanism of action (MoA) for inhibiting FXI activation to Factor XIa (FXIa) was discovered by applying an AS-MS-based screen to the FXI zymogen. Biochemical and biophysical characterization of these structurally diverse small-molecule classes confirmed this mode of inhibition as specific to the FXI zymogen, and a high-resolution FXI-inhibitor cocomplex structure identified the binding pocket that is distal to the FXI cleavage site. These FXI Activation Inhibitors were active in translational functional assays, prolonging activated partial thromboplastin time (aPTT) in human plasma and demonstrating dose-dependent antithrombotic effects in the rabbit arteriovenous-shunt model of thrombosis. The results affirm that FXI Activation Inhibitors are a novel mechanism for the potential treatment of thrombotic disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quantitative Biosciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
- Discovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
- In Vivo Pharmacology, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
ORCID-Profile: Anthony Ogawa, Christopher M Barbieri, Elliott Nickbarg, Amjad Ali
Zitieren
APA
Ellsworth, K., Nizner, P., Ogawa, A., Hruza, A., Wei, L., Yang, D., Lombardo, M., Sonatore, L., Barbieri, C. M., Wickham, A., Chamberlin, C., Nickbarg, E., Richards, M., Sauvagnat, B., Ziebell, M., Ho, T., Ali, A., Hicks, J., Sheth, P., & Tata, J. (2025). The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors. ACS Pharmacology & Translational Science, 8(9), 3090-3100. https://doi.org/10.1021/acsptsci.5c00265
Vancouver
Ellsworth K, Nizner P, Ogawa A, Hruza A, Wei L, Yang D, et al. The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors. ACS Pharmacology & Translational Science. 2025;8(9):3090-3100. doi:10.1021/acsptsci.5c00265
BibTeX
@article{Ellsworth2025,
author = {Ellsworth, Ken and Nizner, Peter and Ogawa, Anthony and Hruza, Alan and Wei, Lan and Yang, Dexi and Lombardo, Matthew and Sonatore, Lisa and Barbieri, Christopher M and Wickham, Alexandra and Chamberlin, Chad and Nickbarg, Elliott and Richards, Matthew and Sauvagnat, Berengere and Ziebell, Michael and Ho, Thu and Ali, Amjad and Hicks, Jacqueline and Sheth, Payal and Tata, Jim},
title = {The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors},
journal = {ACS Pharmacology & Translational Science},
year = {2025},
volume = {8},
number = {9},
pages = {3090--3100},
doi = {10.1021/acsptsci.5c00265}
}
EUVIMED